Unraveling the Complexity of Severe Asthma Treatment
Released On
November 30, 2022
Expires On
November 30, 2023
Media Type
Internet
Completion Time
60 minutes
Specialty
Allergy & Immunology, Pulmonology
Topic(s)
Asthma
Scroll to the Bottom of this Information to Begin this Course
This activity is provided by National Jewish Health.
This activity is supported by an educational grant from AstraZeneca Pharmaceuticals.
Credit Available
- Physicians — maximum of 1.0 AMA PRA Category 1 Credit™
All other healthcare professionals completing this course will be issued a statement of participation.
Target Audience
This activity is designed to meet the educational needs of Pulmonologists, Allergists, Nurse Practitioners and Physician Assistants in those specialties.
Program Overview
The past two decades of research in severe asthma have changed our understanding of this complex, heterogeneous condition that includes a host of inflammatory subtypes and clinical manifestations with variations in endotype, phenotype and biomarkers/cytokines. Newly approved and emerging therapies that target the epithelial alarmins represent an important opportunity to improve outcomes for patients with a broad range of asthma phenotypes.
This activity will unravel the complexity of severe asthma treatment by providing expert insights into the new paradigm of treatments. Topics include the role of the epithelium in severe asthma, the downstream effect on alarmins, airway hyperrresonsiveness, and matching phenotypes to therapeutic approaches for improved patient care.
Learning Objectives
Upon completion of this activity, participants should be better able to:
- Describe the role of the airway epithelium in asthma.
- Define the epithelial alarmins and their impact on T2 and non-T2 airway inflammation, remodeling, and hyper responsiveness in severe asthma.
- Evaluate the results of clinical trials of current and emerging therapies that target the epithelial alarmins in severe asthma.
- Match clinical characteristics and phenotypes to treatment targets.
Faculty
Ronald Balkissoon, MD, MSc, DIH, FRCPC
Pulmonary Consultant
Department of Medicine
National Jewish Health
Denver, Colorado
Monica Kraft, MD
System Chair
Samuel Bronfman Department of Medicine
Icahn School of Medicine at Mount Sinai
Mount Sinai Health System
New York, NY
Flavia Cecilia Lega Hoyte, MD
Associate Professor of Medicine
Fellowship Training Program Director
Division of Allergy and Immunology
National Jewish Health
University of Colorado
Denver, CO
Physician Accreditation Statement
National Jewish Health is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physician Credit Designation
National Jewish Health designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosures of Conflicts of Interest
In accordance with the Accreditation Council for Continuing Medical Education (ACCME), National Jewish Health requires that all program faculty, content developers, reviewers, and others in a position to control the content of this activity disclose to learners the presence or absence of any relevant financial relationships with an ACCME-defined ineligible company within the preceding 24 months of the activity. The ACCME defines an “ineligible company” as one whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
Our goal is to ensure that there is no compromise in the ethical relationship that exists between those in a position to control the content of the activity and those participating in the activity and their respective professional duties. All accredited education activities offered by National Jewish Health are reviewed to ensure a balanced and evidence-based presentation.
All relevant financial relationships among individuals in a position to control the content of this activity have been identified and mitigated according to the Standards of Integrity and Independence in Accredited Continuing Education.
- Faculty
-
- Ronald Balkissoon, MD, MSc, DIH, FRCPC discloses he is a speaker for AstraZeneca Pharmaceuticals and Genentech. He is also on advisory boards for AstraZeneca Pharmaceuticals, Genentech, GlaxoSmithKline, Sanofi, and Regeneron.
- Flavia Hoyte, MD discloses she is an investigator for AstraZeneca Pharmaceuticals, Genentech, Regeneron, Sanofi, and TEVA Pharmaceuticals. She is also a consultant for Genentech and a speaker and advisory board member for AstraZeneca Pharmaceuticals. She is a stockholder in Amgen and was previously a speaker for GlaxoSmithKline.
- Monica Kraft, MD discloses she was previously on advisory boards for AstraZeneca Pharmaceuticals, Chiesi Pharmaceuticals, Sanofi Regeneron, and was previously a consultant for AstraZeneca Pharmaceuticals and a speaker for Chiesi Pharmaceuticals.
- Planners and Reviewers
-
- Harold Nelson, MD discloses he is a consultant for ALK and is on the Data Safety Monitoring Board for AstraZeneca Pharmaceuticals.
- Zulma Yunt, MD has no relevant financial relationships to disclose.
- Meghan Brenner, MA has no relevant financial relationships to disclose.
- Elyce Bowron, MEd has no relevant financial relationships to disclose.
- Andrea Harshman, MHA, CHCP, CMP-HC has no relevant financial relationships to disclose.
Instructions for Participation and Credit
There are no fees for participating and receiving CME credit for this enduring activity. To receive CME credit participants must:
- Read the CME/CE information and faculty disclosures.
- Participate in the online activity.
- Submit the evaluation form and complete the post-test with a passing score of at least 75%.
Certificates will be emailed to the participant.
Course Viewing Requirements
Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.
No endorsement of unapproved products or uses is made or implied by coverage of these products or uses.
Please refer to the official prescribing information for each product for discussion of approved indicators, contraindications, and warnings.
Disclaimer
National Jewish Health (“NJH”) and its officers, Board of Directors, faculty, employees, representatives, and other agents (collectively, “NJH Parties”) shall not be responsible in any capacity for, and do not warrant any content whatsoever, in any NJH publication or other product (in any medium), or the use or reliance on any such content, and expressly disclaim any and all liability for such content. All such responsibility for content and use of product solely rests with the authors or the advertisers, as the case may be.
By way of example, without limiting the foregoing, this disclaimer of liability applies to the accuracy, completeness, effectiveness, quality, appearance, ideas, or products, as the case may be, of or resulting from, any statements, references, articles, positions, claimed diagnosis, claimed possible treatments, services, or advertising, express or implied, contained in any NJH live meeting, publication, online course or other product.
Furthermore, the content should not be considered medical advice and is not intended to replace consultation with a qualified medical professional. Under no circumstances, including negligence, shall any of the NJH Parties be liable for any DIRECT, INDIRECT, INCIDENTAL, SPECIAL or CONSEQUENTIAL DAMAGES, or LOST PROFITS that result from any of the foregoing, regardless of legal theory and whether or not claimant was advised of the possibility of such damages.
Contact Information
For CME questions please contact: Proed@njhealth.org.